JP7719725B2 - Ａ型インフルエンザ感染の抗体及び治療法 - Google Patents

Ａ型インフルエンザ感染の抗体及び治療法

Info

Publication number
JP7719725B2
JP7719725B2 JP2021562803A JP2021562803A JP7719725B2 JP 7719725 B2 JP7719725 B2 JP 7719725B2 JP 2021562803 A JP2021562803 A JP 2021562803A JP 2021562803 A JP2021562803 A JP 2021562803A JP 7719725 B2 JP7719725 B2 JP 7719725B2
Authority
JP
Japan
Prior art keywords
antibody
nucleic acid
present
seq
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531556A5 (https=
JPWO2020221908A5 (https=
JP2022531556A (ja
Inventor
ダヴィデ・コルティ
ファビオ・ベニーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of JP2022531556A publication Critical patent/JP2022531556A/ja
Publication of JP2022531556A5 publication Critical patent/JP2022531556A5/ja
Publication of JPWO2020221908A5 publication Critical patent/JPWO2020221908A5/ja
Application granted granted Critical
Publication of JP7719725B2 publication Critical patent/JP7719725B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021562803A 2019-04-30 2020-04-30 Ａ型インフルエンザ感染の抗体及び治療法 Active JP7719725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2019/061134 WO2020221450A1 (en) 2019-04-30 2019-04-30 Antibodies and methods for treatment of influenza a infection
EPPCT/EP2019/061134 2019-04-30
PCT/EP2020/062160 WO2020221908A1 (en) 2019-04-30 2020-04-30 Antibodies and methods for treatment of influenza a infection

Publications (4)

Publication Number Publication Date
JP2022531556A JP2022531556A (ja) 2022-07-07
JP2022531556A5 JP2022531556A5 (https=) 2023-05-02
JPWO2020221908A5 JPWO2020221908A5 (https=) 2023-05-02
JP7719725B2 true JP7719725B2 (ja) 2025-08-06

Family

ID=66429359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562803A Active JP7719725B2 (ja) 2019-04-30 2020-04-30 Ａ型インフルエンザ感染の抗体及び治療法

Country Status (17)

Country Link
US (1) US20220226470A1 (https=)
EP (1) EP3962530A1 (https=)
JP (1) JP7719725B2 (https=)
KR (1) KR20220003000A (https=)
CN (2) CN114269381A (https=)
AU (1) AU2020265407B2 (https=)
BR (1) BR112021018409A2 (https=)
CA (1) CA3132536A1 (https=)
CL (1) CL2021002807A1 (https=)
CO (1) CO2021012583A2 (https=)
EA (1) EA202192923A1 (https=)
IL (1) IL287423A (https=)
MX (1) MX2021012984A (https=)
PH (1) PH12021552176A1 (https=)
SG (1) SG11202109683TA (https=)
TW (1) TW202106707A (https=)
WO (2) WO2020221450A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102820941B1 (ko) 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
IL290752B2 (en) * 2019-08-29 2026-02-01 Vir Biotechnology Inc Preparations and methods for treating influenza a infection
US20230340083A1 (en) * 2020-12-08 2023-10-26 Vir Biotechnology, Inc. Antibodies and methods for treatment of influenza a infection
CN112812095A (zh) * 2021-01-29 2021-05-18 成都安满生物医药科技有限公司 一种巴洛沙韦酯中间体的合成方法
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
CN115777944B (zh) * 2023-02-10 2023-05-12 北京衡美金叶营养健康科技有限公司 增强身体防御力的组合物及其制备方法和应用
IL325937A (en) * 2023-07-24 2026-03-01 Univ Miami AAV-delivered antibodies and methods of using them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502262A (ja) 2010-11-12 2014-01-30 ザ ロックフェラー ユニバーシティ Ｈｉｖ治療用の融合タンパク質
JP2016505559A (ja) 2012-12-07 2016-02-25 ファイザー・インク 操作された単量体抗体断片
JP2016538876A (ja) 2013-10-02 2016-12-15 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン，エルエルシー Ａ型インフルエンザを治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502262A (ja) 2010-11-12 2014-01-30 ザ ロックフェラー ユニバーシティ Ｈｉｖ治療用の融合タンパク質
JP2016505559A (ja) 2012-12-07 2016-02-25 ファイザー・インク 操作された単量体抗体断片
JP2016538876A (ja) 2013-10-02 2016-12-15 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン，エルエルシー Ａ型インフルエンザを治療する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nat. Biotechnol.，2010年，Vol.28，pp.157-159

Also Published As

Publication number Publication date
EP3962530A1 (en) 2022-03-09
WO2020221450A1 (en) 2020-11-05
PH12021552176A1 (en) 2022-09-12
CO2021012583A2 (es) 2021-10-20
CA3132536A1 (en) 2020-11-05
CL2021002807A1 (es) 2022-08-19
AU2020265407A1 (en) 2021-10-07
CN114269381A (zh) 2022-04-01
EA202192923A1 (ru) 2022-02-16
US20220226470A1 (en) 2022-07-21
AU2020265407B2 (en) 2026-01-08
TW202106707A (zh) 2021-02-16
KR20220003000A (ko) 2022-01-07
SG11202109683TA (en) 2021-11-29
BR112021018409A2 (pt) 2021-11-23
MX2021012984A (es) 2021-12-10
CN119192357A (zh) 2024-12-27
IL287423A (en) 2021-12-01
WO2020221908A1 (en) 2020-11-05
JP2022531556A (ja) 2022-07-07

Similar Documents

Publication Publication Date Title
JP7719725B2 (ja) Ａ型インフルエンザ感染の抗体及び治療法
JP6595448B2 (ja) 治療効率の増強のために鼻腔内送達する中和抗体に基づく組成物および方法
EP2846832B1 (en) Novel ha binding agents
CN102216327A (zh) 中和抗甲型流感病毒抗体及其用途
JP2022521819A (ja) インフルエンザを処置および予防するための組成物および方法
US20230340083A1 (en) Antibodies and methods for treatment of influenza a infection
US20220306728A1 (en) Compositions and methods for treatment of influenza a infection
HK40067817A (en) Antibodies and methods for treatment of influenza a infection
EA048000B1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
EA050175B1 (ru) Композиции и способы лечения инфекции, вызываемой вирусом гриппа а
HK40074693A (en) Compositions and methods for treatment of influenza a infection
HK40035221A (en) Novel ha binding agents
HK1208619B (en) Novel ha binding agents

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250519

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250725

R150 Certificate of patent or registration of utility model

Ref document number: 7719725

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150